2018
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Failure 2018, 5: 1035-1043. PMID: 30120812, PMCID: PMC6300815, DOI: 10.1002/ehf2.12334.Peer-Reviewed Original ResearchConceptsWeight loss agentsHeart failureEjection fractionHF hospitalizationNew York Heart Association functional class IIIGlucagon-like peptide-1 (GLP-1) receptor antagonistHeart Failure Treatment studyWeight lossAcute HF hospitalizationEfficacy of liraglutideRecent HF hospitalizationFunctional class IIILast study visitReduced ejection fractionAdvanced heart failureCardiovascular outcome trialsMedian ejection fractionAnalysis of patientsLiraglutide useMultivariable adjustmentStudy drugObese patientsOutcome trialsMedian agePrimary outcome
2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Östergren J, Ibsen H, Weber M, Investigators F. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. Blood Pressure 2008, 17: 7-17. PMID: 18568687, DOI: 10.1080/08037050801972857.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAntihypertensive AgentsBenzazepinesBlood PressureDose-Response Relationship, DrugDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleFinlandHumansHydrochlorothiazideHypertensionMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsRacial GroupsRisk AssessmentScandinavian and Nordic CountriesTreatment OutcomeUnited StatesConceptsBlood pressureBP controlCombination therapyBaseline predictorsBP valuesCombination treatmentAbsolute BP valuesMain baseline predictorsPrevious antihypertensive medicationsLipid-lowering therapyUncontrolled blood pressureBlood pressure responseLarge outcome trialsLipid-lowering drugsSystolic BP valuesLogistic regression modelsBlinded baselineUncontrolled hypertensionAntihypertensive medicationsCardiovascular eventsSevere hypertensionSystolic hypertensionThiazide useOutcome trialsOverall patients